DSGN Reports $219.8M Cash, $13.4M Qtr R&D, $69.8M Yr Net Loss, Advances DT-216P2 FA, DT-168 FECD, DT-818 DM1 Trials
Design Therapeutics, Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $10.44
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS